Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher McGuigan

Showing results (91-100 of 152) with videos related to

Pageof 16
Sort By:
European Journal of Medicinal Chemistry|February 9, 2016
Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cellsSahar Kandil, Jennifer M Wymant, Benson M Kariuki, et al.
International Journal of Ophthalmology|August 3, 2022
Neuromyelitis optica spectrum disorders and anti-myelin oligodendrocyte glycoprotein positive optic neuropathiesPatrick Murtagh, Amy Coman, Kirk Stephenson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 24, 2020
Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complicationsMartijn T Wijburg, Clemens Warnke, Christopher McGuigan, et al.
Multiple Sclerosis and Related Disorders|October 7, 2021
Five-year follow up of the original Irish BICAMS validation cohortMaria Gaughan, Ruth Monaghan, Karen O'Connell, et al.
Nucleosides, Nucleotides & Nucleic Acids|November 12, 2003
Phosphoramidate protides of 2',3'-dideoxy-3'-fluoroadenosine and related nucleosides with potent activity against HIV and HBVKristjan S Gudmundsson, Susan M Daluge, Lance C Johnson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 3, 2007
The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical)Lisa Costelloe, Killian O'Rourke, Hugh Kearney, et al.
Antiviral Chemistry & Chemotherapy|September 20, 2002
Alkyloxyphenyl furano pyrimidines as potent and selective anti-VZV agents with enhanced water solubilityChristopher McGuigan, Sally Blewett, Dario Siccardi, et al.
Nucleosides, Nucleotides & Nucleic Acids|January 5, 2005
Phosphoramidate protides of carbocyclic 2',3'-dideoxy-2',3'-didehydro-7-deazaadenosine with potent activity against HIV and HBVKristjan S Gudmundsson, Zhicheng Wang, Susan M Daluge, et al.
Multiple Sclerosis and Related Disorders|June 23, 2024
Neuropsychology intervention for managing invisible symptoms of MS (NIMIS-MS) group: A pilot effectiveness and acceptability studyFiadhnait O'Keeffe, Clodagh Cogley, Caoimhe McManus, et al.
International Journal of Pharmaceutics|August 24, 2005
Preferential pi-pi complexation between tamoxifen and borage oil/gamma linolenic acid: transcutaneous delivery and NMR spectral modulationCharles M Heard, Simon J Gallagher, Costantino Congiatu, et al.
Pageof 16

Showing results (91-100 of 152) with videos related to

Sort By:
Pageof 16
European Journal of Medicinal Chemistry|February 9, 2016
Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cellsSahar Kandil, Jennifer M Wymant, Benson M Kariuki, et al.
International Journal of Ophthalmology|August 3, 2022
Neuromyelitis optica spectrum disorders and anti-myelin oligodendrocyte glycoprotein positive optic neuropathiesPatrick Murtagh, Amy Coman, Kirk Stephenson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 24, 2020
Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complicationsMartijn T Wijburg, Clemens Warnke, Christopher McGuigan, et al.
Multiple Sclerosis and Related Disorders|October 7, 2021
Five-year follow up of the original Irish BICAMS validation cohortMaria Gaughan, Ruth Monaghan, Karen O'Connell, et al.
Nucleosides, Nucleotides & Nucleic Acids|November 12, 2003
Phosphoramidate protides of 2',3'-dideoxy-3'-fluoroadenosine and related nucleosides with potent activity against HIV and HBVKristjan S Gudmundsson, Susan M Daluge, Lance C Johnson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 3, 2007
The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical)Lisa Costelloe, Killian O'Rourke, Hugh Kearney, et al.
Antiviral Chemistry & Chemotherapy|September 20, 2002
Alkyloxyphenyl furano pyrimidines as potent and selective anti-VZV agents with enhanced water solubilityChristopher McGuigan, Sally Blewett, Dario Siccardi, et al.
Nucleosides, Nucleotides & Nucleic Acids|January 5, 2005
Phosphoramidate protides of carbocyclic 2',3'-dideoxy-2',3'-didehydro-7-deazaadenosine with potent activity against HIV and HBVKristjan S Gudmundsson, Zhicheng Wang, Susan M Daluge, et al.
Multiple Sclerosis and Related Disorders|June 23, 2024
Neuropsychology intervention for managing invisible symptoms of MS (NIMIS-MS) group: A pilot effectiveness and acceptability studyFiadhnait O'Keeffe, Clodagh Cogley, Caoimhe McManus, et al.
International Journal of Pharmaceutics|August 24, 2005
Preferential pi-pi complexation between tamoxifen and borage oil/gamma linolenic acid: transcutaneous delivery and NMR spectral modulationCharles M Heard, Simon J Gallagher, Costantino Congiatu, et al.
Pageof 16